苯酰甲硝唑结构式
|
常用名 | 苯酰甲硝唑 | 英文名 | Metronidazole Benzoate |
|---|---|---|---|---|
| CAS号 | 13182-89-3 | 分子量 | 194.184 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 372.3±27.0 °C at 760 mmHg | |
| 分子式 | C13H13N3O4 | 熔点 | 102 °C | |
| MSDS | N/A | 闪点 | 150.5±17.2 °C |
苯酰甲硝唑用途Metronidazole Benzoate 衍生自甲硝唑和苯甲酸,具有抗菌,抗寄生虫,抗滴虫等作用。 |
| 中文名 | 苯酰甲硝唑 |
|---|---|
| 英文名 | metronidazole benzoate |
| 中文别名 | 灭滴灵 | 1-(2-苯甲酰氧乙基)-5-硝基-2-甲基咪唑 | 1-(2-苯甲酰氧乙基)-2-甲基-5-硝基咪唑 | 苯甲酸甲硝唑 |
| 英文别名 | 更多 |
| 描述 | Metronidazole Benzoate 衍生自甲硝唑和苯甲酸,具有抗菌,抗寄生虫,抗滴虫等作用。 |
|---|---|
| 相关类别 | |
| 靶点 |
Antibacterial, antimicrobial, antiparasitic, antitrichomonal[1] |
| 体外研究 | 苯甲酸甲硝唑用于治疗多种厌氧菌、原生动物和类细菌引起的感染,包括滴虫病、阿米巴病、阴道病和牙龈炎[1]。 |
| 参考文献 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 沸点 | 372.3±27.0 °C at 760 mmHg |
| 熔点 | 102 °C |
| 分子式 | C13H13N3O4 |
| 分子量 | 194.184 |
| 闪点 | 150.5±17.2 °C |
| 精确质量 | 194.057907 |
| PSA | 89.94000 |
| LogP | 1.64 |
| 外观性状 | 固体;White to Light yellow powder to crystal |
| 蒸汽压 | 0.0±0.9 mmHg at 25°C |
| 折射率 | 1.627 |
| 储存条件 | 0-10°C;存放于惰性气体之中;避免空气,加热 |
| 计算化学 | 1.疏水参数计算参考值（XlogP）:无 2.氢键供体数量:0 3.氢键受体数量:5 4.可旋转化学键数量:5 5.互变异构体数量:无 6.拓扑分子极性表面积:89.9 7.重原子数量:20 8.表面电荷:0 9.复杂度:352 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
| 危险品运输编码 | NONH for all modes of transport |
|---|---|
| 海关编码 | 2933990090 |
|
~86%
苯酰甲硝唑 13182-89-3 |
| 文献：Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, , vol. 48, # 11 p. 1571 - 1576 |
|
~37%
苯酰甲硝唑 13182-89-3 |
| 文献：European Journal of Medicinal Chemistry, , vol. 32, # 12 p. 995 - 1000 |
| 苯酰甲硝唑上游产品 3 | |
|---|---|
| 苯酰甲硝唑下游产品 2 | |
| 海关编码 | 2933290090 |
|---|---|
| 中文概述 | 2933290090. 其他结构含非稠合咪唑环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期 |
| Summary | 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
The treatment of Trichomonas vaginalis vaginitis. An open controlled prospective study comparing a single dose of metronidazole tablets, benzoyl metronidazole suspension and tinidazole tablets.
S. Afr. Med. J. 67(12) , 455-7, (1985) Metronidazole tablets, benzoyl metronidazole suspension and tinidazole tablets each given as a single 2 g bolus dose in an open controlled prospective study were found to be effective forms of treatme... |
|
|
Use of Klion suspension in paediatry and gynaecology.
Ther. Hung. 40(4) , 189-91, (1992) Klion suspension was given to 42 girl and woman patients suffering from vaginal trichomoniasis. Negativity for Trichomonas was recorded in 73.8% of the cases in response to the first 10-day cure, and ... |
|
|
Trichomonas infection in pregnancy--does it affect perinatal outcome?
S. Afr. Med. J. 63(15) , 566-7, (1983) Antenatal patients free of Trichomonas vaginalis vaginal infection were compared with infected patients, half of whom were treated and half left untreated. The treated group was given benzoylmetronida... |
| (E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid |
| caffeic acid 3-methyl ether |
| Benzoylmetronildazole |
| Coniferic acid |
| (E)-4-hydroxy-3-methoxy-Cinnamic acid |
| (E)-4-Hydroxy-3-methoxycinnamic acid |
| MFCD00239523 |
| (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid |
| 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (2E)- |
| Metronidazole Benzoate |
| (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid |
| (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid |
| (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid |
| 2-Methyl-5-nitro-1H-imidazole-1-ethyl benzoate |
| Ferulic acid |
| Ferulic acid, trans- |
| 3-(4-Hydroxy-3-methoxyphenyl)propenoic acid |
| 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate |
| (2E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid |
| EINECS 236-131-7 |
| 1H-Imidazole-1-ethanol, 2-methyl-5-nitro-, benzoate (ester) |
| Ferulic acid, E- |
查看所有供应商和价格请点击：
